Asclepii Partners with Nottingham Spirk to Scale Breakthrough Regenerative Wound Care Technology Nationwide
Strategic collaboration aims to expand access to next-generation regenerative platform designed to improve healing outcomes and reduce the cost of chronic wound care
CLEVELAND, OH — Chronic wounds affect millions of Americans each year, leading to prolonged suffering, preventable amputations, and billions of dollars in healthcare costs.
Asclepii, a Cleveland-based regenerative medicine company pioneering advanced wound healing solutions, today announced a strategic partnership with Nottingham Spirk, a leading product innovation and commercialization firm, to accelerate large-scale manufacturing and deployment of its flagship Artemis™ regenerative platform.
The collaboration represents a major milestone in advancing accessible regenerative medicine by combining Asclepii’s breakthrough tissue engineering technology with Nottingham Spirk’s proven expertise in product development, engineering, and commercialization. Nottingham Spirk has generated more than 1,550 patents and over $100 billion in client revenue across multiple industries, with a 95% commercialization success rate.
Together, the organizations aim to expand national access to Artemis — an innovative extracellular matrix (ECM) platform designed to support tissue regeneration and improve healing across a range of chronic and complex wounds, including diabetic foot ulcers, burns, and surgical sites.
Artemis represents a next-generation approach to wound care: a shelf-stable = scaffold engineered to support cellular adhesion, tissue regeneration, and wound stabilization. The platform is designed to provide a durable, clinically practical solution at significantly lower cost than many traditional advanced wound therapies, with the potential to reduce treatment expenses from thousands of dollars per patient to a fraction of that amount, depending on clinical application.
“Patients with chronic wounds often face prolonged healing, high treatment costs, and serious complications that can dramatically impact quality of life,” said Franco Kraiselburd, Founder and CEO of Asclepii. “Scaling innovative regenerative technologies like Artemis is essential to changing that reality. Partnering with Nottingham Spirk brings world-class engineering, design, and commercialization expertise that will allow us to expand production and accelerate access to this technology for patients and providers nationwide.”
Through its Vertical Innovation® process, Nottingham Spirk will support Asclepii in optimizing manufacturing systems, advancing regulatory readiness, and enabling efficient large-scale production to meet growing clinical demand.
“Asclepii’s Artemis platform has the potential to meaningfully improve outcomes in wound care while reducing the economic burden on the healthcare system,” said a spokesperson for Nottingham Spirk. “We’re excited to apply our experience transforming breakthrough concepts into market-leading products and help bring this important technology to patients at scale.”
The partnership also reflects a shared commitment to strengthening U.S. biomanufacturing capabilities, advancing domestic medical innovation, and addressing one of healthcare’s most persistent challenges — chronic wounds that affect millions of individuals, particularly those living with diabetes and vascular disease.
ABOUT ASCLEPII
Asclepii is a U.S.-based medical technology company focused on regenerative medicine and advanced wound healing. Named after Asclepius, the Greek god of healing, Asclepii develops evidence-driven, accessible technologies designed to improve outcomes in complex and chronic wounds. Its flagship Artemis™ platform reimagines tissue engineering to enable scalable, cost-effective regenerative care. Learn more at asclepii.com.
ABOUT NOTTINGHAM SPIRK
Nottingham Spirk is a Cleveland-based business innovation and product design firm renowned for its Vertical Innovation® process. With a 95% commercialization success rate, the firm has generated more than 1,550 patents and over $100 billion in client revenue across consumer goods, medical devices, and industrial sectors. For more information, visit nottinghamspirk.com.
